Corneal thickness after cataract surgery in Fuchs' dystrophy
Part of Eyes & vision, Genetic & congenital clinical trials.
This study looks at how the cornea (the clear front part of the eye) changes after cataract surgery in people with Fuchs' endothelial dystrophy, a condition that affects the inner layer of the cornea. It compares them to people without this condition to see if there are differences in corneal thickness after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older and are scheduled for cataract surgery.
- You have Fuchs' endothelial dystrophy (a condition where the inner layer of the cornea slowly stops working) or you have no known corneal problems.
- You do not have other eye diseases like glaucoma, uveitis, or diabetic retinopathy.
- You have not had any previous eye surgery (including laser procedures).
- You have not had any eye injury in the last 6 months.
- Your corneal thickness is not more than 625 micrometers (a very thick cornea).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a scoring system to predict how well people with Fuchs dystrophy do after cataract surgery. It may help doctors plan better treatment for your cornea and lens.
This study compares two types of cataract surgery in people with Fuchs' dystrophy: one using a laser and the standard method. It looks at which approach gives better results for the cornea and vision.
This study tests special intraocular lenses (lenses placed inside the eye during cataract surgery) that are designed to work well in people who also need cornea transplantation (DMEK procedure). It aims to improve vision and reduce the need for glasses after surgery.
This trial tests a surgical technique called Descemet membrane polishing during corneal transplant surgery for Fuchs endothelial corneal dystrophy, a condition that clouds the cornea (the clear front part of your eye). The study aims to see if this polishing step improves healing and vision after surgery.
This Phase 2 study tests whether eye drops containing a medicine called N-acetylcysteine (NAC) can reduce damaging “reactive oxygen” in people with advanced Fuchs’ endothelial corneal dystrophy (FECD). It involves people who need a special cornea transplant (DMEK) at the same time as cataract surgery, aiming to improve cornea healing and vision.
This trial tests an investigational eye drop (DT-168) in people with Fuchs endothelial corneal dystrophy who are already scheduled for a corneal transplant. The goal is to see if DT-168 can improve outcomes or delay the need for surgery.
Hear when a new Fuchs Endothelial Corneal Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.